Revolution Medicines, Inc.

RVMD · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
108
SEC Filings

Business Summary

Competition for additional information regarding our competitors. This competition and competition with approved therapies will reduce the number and types of patients available for clinical trials involving our product candidates, because some patients who might have opted to enroll in our trials may instead opt to pursue a treatment regimen using an approved therapy or enroll in a trial conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we c...

Next Earnings

Q2 FY2026 — expected 2026-09-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionRVMDdiscussed_in_filing Cybersecurity
topic_mentionRVMDdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-252025-12-310001193125-26-071563EDGAR97K words
2025-02-262024-12-310000950170-25-027736EDGAR—
2024-02-262023-12-310000950170-24-020145EDGAR—
2023-02-272022-12-310000950170-23-004645EDGAR—
2022-02-282021-12-310000950170-22-002297EDGAR—
2021-03-022020-12-310001564590-21-010276EDGAR—
2020-03-302019-12-310001564590-20-014169EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-266923EDGAR69K words
2025-08-062025-06-300000950170-25-104022EDGAR—
2025-05-072025-03-310000950170-25-065660EDGAR—
2024-11-062024-09-300000950170-24-122303EDGAR—
2024-08-072024-06-300000950170-24-092783EDGAR—
2024-05-082024-03-310000950170-24-055655EDGAR—
2023-11-062023-09-300000950170-23-059391EDGAR—
2023-08-082023-06-300000950170-23-039805EDGAR—
2023-05-082023-03-310000950170-23-018805EDGAR—
2022-11-072022-09-300000950170-22-022590EDGAR—
2022-08-092022-06-300000950170-22-016059EDGAR—
2022-05-092022-03-310000950170-22-008496EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-250001193125-26-071517EDGAR3K words
2025-11-050001193125-25-266836EDGAR—
2025-10-170001193125-25-241736EDGAR—
2025-09-100001193125-25-200078EDGAR—
2025-08-060000950170-25-103983EDGAR—
2025-06-270001193125-25-151254EDGAR—
2025-06-240001193125-25-145242EDGAR—
2025-06-180001193125-25-142735EDGAR—
2025-05-070000950170-25-065618EDGAR—
2025-02-260000950170-25-027707EDGAR—

108 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001628171
TickerRVMD
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 03c68f0664a19cd2be28ccfdf6d43441a6301c4b79b3410c81c92464e256a377
parent: 564440944cd303f5e6195a46660ec13291e1c10f7274c46b236d641c4a094ea2
content hash: 02407baf1121e5863e6dc1f656850f03155828332b0be689ec4c1c49b02b9542
signed: 2026-04-13T04:47:16.899Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf